Ascendis Pharma (ASND) Tops Q2 EPS by 45c

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR0.82), EUR0.45 better than the analyst estimate of (EUR1.27). Revenue for the quarter came in at EUR158.05 million versus the consensus estimate of EUR142.38 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Ferguson Plc. (FERG) to Neutral, 'We now see better opportunities elsewhere in our coverage'
• Patterson-UTI averaged 95 rigs in June, 92 for Q2 2026
• Toyota Will Move Tacoma Production Back To U.S. - WSJ